| Management target | Net Profit FY27 |
|---|
| Margins | Consolidated EBITDA margin improved 53 bps to 15.0%. |
|---|---|
| Demand visibility | Strong pipeline for specialty chemicals and premium spirits. |
Growth
Net revenue reached ₹1,130 Cr (+9% YoY), EBITDA rose to ₹170 Cr (+13%), and PAT increased to ₹97 Cr.
Outlook
NCLT-approved demerger to create focused entities; targeting ₹1,000 Cr Spirits EBITDA in 4-5 years and debt-free status by FY28.
Risks
Rising crude prices impacting competitiveness and raw material availability for bio-pharma segments.
Last quarter's promises, checked
Delivered
- Targeted NCLT demerger order by June 2026 → Delivered order on 17 July 2026 (= BEAT)
- Guided debt reduction via prepayments → Delivered ₹804 Cr prepaid in Q4FY26 (= BEAT)
- Planned 'Jamun Flavour' launch → Delivered launch in current quarter (= BEAT)
Partly delivered
- Guided Chemicals growth via higher value-added portfolio → Delivered +20.6% revenue but margins remain sensitive to crude (= PARTIAL)
Investor Presentation filed with BSE, NSE: INDIAGLYCO. Summary written with AI assistance from the document.
India Glycols Ltd: key numbers
- Share price
- ₹382.70
- Market cap
- ₹2,565 Cr
- Revenue (annual)
- ₹4,211 Cr
- Net profit (annual)
- ₹292.8 Cr
- P/E (TTM)
- 8.1×Sector 36.8×
- Promoter holding
- 59.63%+0.00% QoQ
- FII holding
- 2.24%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from India Glycols Ltd
All →India Glycols Board Meeting Outcome
India Glycols Limited announced that its subsidiary, IGL Spirits Limited, approved share allotment under a Scheme of Arrangement and appointed new key managerial personnel.
India Glycols Management Change
India Glycols Ltd announced that four senior management personnel ceased their roles following the effective date of a previously disclosed Scheme of Arrangement.
India Glycols Merger & Restructuring
India Glycols Limited has completed its demerger into three separate entities effective September 1, 2026. The scheme, sanctioned by the NCLT, is now operational.
India Glycols Management Change
India Glycols' subsidiary, Ennature Bio Pharma, announced the appointment of new Directors and a Managing Director. These appointments are part of ongoing corporate updates.
India Glycols Merger & Restructuring
India Glycols Ltd received the certified NCLT order approving the Scheme of Arrangement, which involves the demerger of its Biopharma, Spirits, and Biofuel undertakings.
India Glycols Annual General Meeting
India Glycols held its 42nd Annual General Meeting on August 19, 2026. Shareholders approved all resolutions, including the final dividend payout.